Avadel Pharmaceuticals (AVDL) Event Aug. 05, 2022, 20:58 UTC (99% Neutral) AVADEL PHARMACEUTICALS PLC (AVDL) Announces Regulatory Update Full text
Register to leave comments News bot Oct. 2, 2025, 9:45 p.m. 📋 AVADEL PHARMACEUTICALS PLC (AVDL) - Regulatory Update Filing Date: 2022-08-05 Accepted: 2022-08-05 16:58:57 Event Type: Regulatory Update Event Details: Avadel Pharmaceuticals (AVDL) Announces Regulatory Update Avadel Pharmaceuticals (AVDL) provided an update on regulatory developments for its product portfolio. Regulatory Update Details: None Clinical Development: 🔬 Clinical Development Pipeline (AVADEL PHARMACEUTICALS PLC): Product Type Development Stage Therapeutic Area Source LUMRYZ DRUG Preclinical Narcolepsy ClinicalTrials.gov FT218 DRUG Phase PHASE3 Narcolepsy ClinicalTrials.gov 💼 Business Developments: Partnership: Not availableAcquisition: Not availableLicensing: Not availableRegulatory ApprovalExecutive Changes: Not available Structured Data: Company Name: Avadel PharmaceuticalsCIK: 0001012477Ticker Symbol: AVDLPeriod End Date: 2022-08-04Document Type: 8-K
📋 AVADEL PHARMACEUTICALS PLC (AVDL) - Regulatory Update
Filing Date: 2022-08-05
Accepted: 2022-08-05 16:58:57
Event Type: Regulatory Update
Event Details:
🔬 Clinical Development Pipeline (AVADEL PHARMACEUTICALS PLC):
💼 Business Developments:
Structured Data: